Year All202620252024202320222021202020192018201720162015 media@replimune.com Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting April 27, 2026 Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma April 10, 2026 Replimune to Present at Two Upcoming Investor Conferences March 2, 2026 Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update February 3, 2026
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting April 27, 2026
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma April 10, 2026
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update February 3, 2026